SCHEMBL30616243

SCHEMBL30616243

CC(=O)/C(C)=N/NC(=O)Oc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
MAPT P10636 5/20 0.50
GAA P10253 4/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.45
RAB9A P51151 5/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NPC1 O15118 3/20 0.45
KDM4E B2RXH2 2/20 0.45
GLA P06280 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
THRB P10828 1/20 0.43
GFER P55789 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
RAD51 Q06609 1/20 0.41
HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14938455 0.81 MAPT (0.64) ALDH1A1MAPTGAASMN1; SMN2CYP1A2
SCHEMBL14938620 0.80 GAA (0.48) ALDH1A1MAPTGAAHTTSMN1; SMN2
SCHEMBL14938622 0.80 GAA (0.48) ALDH1A1MAPTGAAHTTSMN1; SMN2
SCHEMBL14938436 0.78 ALDH1A1 (0.51) ALDH1A1MAPTGAAHTTSMN1; SMN2
SCHEMBL14938510 0.78 ALDH1A1 (0.48) ALDH1A1MAPTGAACYP1A2RAB9A
SCHEMBL14938458 0.77 ALDH1A1 (0.53) ALDH1A1MAPTSMN1; SMN2CYP1A2RAB9A
SCHEMBL8877445 0.77 ALDH1A1 (0.44) ALDH1A1MAPTGAAHTTSMN1; SMN2
SCHEMBL14950318 0.75 RAB9A (0.69) ALDH1A1MAPTGAASMN1; SMN2RAB9A
SCHEMBL14950270 0.75 CYP1A2 (0.44) ALDH1A1MAPTGAAHTTSMN1; SMN2
SCHEMBL11469499 0.75 POLB (0.53) ALDH1A1MAPTGAAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250248998-A1 LRRK2 Inhibitors Brenig Therapeutics, Inc. 2025-08-07 US disclosed
EP-4504722-A2 LRRK2 INHIBITORS Brenig Therapeutics, Inc. (US) 2025-02-12 EP disclosed
WO-2023196720-A2 LRRK2 INHIBITORS Brenig Therapeutics, Inc. (US) 2023-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250248998-A1 LRRK2 Inhibitors LRRK2, PARK7, PINK1 ALDH1A1 2670/4885MAPT 40/4885GAA 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.